-+ 0.00%
-+ 0.00%
-+ 0.00%

China Biopharmaceutical (01177): TQB2102 “HER2 double epitope ADC” released two clinical data in 2026 ESMO

Zhitongcaijing·10/26/2026 00:25:03
Listen to the news

Zhitong Financial App News, China Biopharmaceutical (01177) announced that the national Class 1 innovative drug TQB2102 “HER2 biepitope ADC” independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), announced two clinical data at the 2026 European Society of Medical Oncology (ESMO) annual meeting, and were selected for the conference's Preferred Oral Report (Proffered Paper (LBA)) and Rapid Oral Report (Rapid Oral) respectively.

TQB2102 is a next-generation HER2 double epitope antibody conjugate drug (ADC) that can simultaneously target the ECD 2 and ECD 4 domains of HER2, and uses lyzable ligands and topoisomerase I inhibitors, which can break through the limitations of traditional HER2 monoclonal antibodies or single-target ADCs, further enhance receptor crosslinking and endocytosis efficiency, expand coverage of tumor heterogeneity, and overcome single-target drug resistance.